Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
A Phase II randomized trial will be initiated to evaluate closure of the perforated tympanic
membrane as the primary measureable outcome. The goal is to determine the safety and efficacy
of Fibroblast Growth Factor-2 (FGF-2) in the closure of chronic tympanic membrane
perforations (TMP). If FGF-2 is topically applied for the treatment of chronic TMP in humans,
it is hypothesized it will be safe, tolerable and effective for use as treatment for tympanic
membrane perforation. A total of 60 subjects will be recruited.